Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Biochemistry

• Publication date

  1998-04-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/BI973011MPMID 9585555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ

  1997cited by this paper
• Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding.

  1996cited by this paper
• Mechanistic studies on the cytochrome P450-catalyzed dehydrogenation of 3-methylindole.

  1996cited by this paper
• Evidence for a 1-Electron Oxidation Mechanism in N-Dealkylation of N,N-Dialkylanilines by Cytochrome P450 2B1

  1996cited by this paper
• The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.

  1996cited by this paper
• Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues.

  1996cited by this paper
• Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.

  1996cited by this paper
• Radical cation intermediates in N-dealkylation reactions.

  1995cited by this paper
• Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2.

  1994cited by this paper
• Theory for the observed isotope effects on the formation of multiple products by different kinetic mechanisms of cytochrome P450 enzymes.

  1994cited by this paper
• CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans.

  1994cited by this paper
• Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.

  1993cited by this paper
• Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2.

  1993cited by this paper
• Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.

  1993cited by this paper
• Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.

  1990cited by this paper
• Isotope effect studies on the mechanism of the cytochrome P-450IIA1-catalyzed formation of delta 6-testosterone from testosterone.

  1990cited by this paper
• Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

  1990cited by this paper
• Mechanisms of activation of phenacetin to reactive metabolites by cytochrome P-450: a theoretical study involving radical intermediates.

  1990cited by this paper
• Deuterium isotope effects on toluene metabolism. Product release as a rate-limiting step in cytochrome P-450 catalysis.

  1989cited by this paper
• Cytochrome P-450 catalysis: radical intermediates and dehydrogenation reactions.

  1989cited by this paper
• Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies.

  1988cited by this paper
• Epileptic discharges induced by intermittent light stimulation in photosensitive baboons: a current source density study.

  1988cited by this paper
• Accumulation of caffeine in healthy volunteers treated with furafylline.

  1987cited by this paper
• Stereochemical dynamics of aliphatic hydroxylation by cytochrome P-450.

  1986cited by this paper
• Glutathione adduct formation with microsomally activated metabolites of the pulmonary alkylating and cytotoxic agent, 3-methylindole.

  1985cited by this paper
• Metabolism of [p-18O]-phenacetin: the mechanism of activation of phenacetin to reactive metabolites in hamsters.

  1979cited by this paper

• Probing into the plasma stability and microsomal stability of thiol-based prodrug derivatives: Using IYS-15, an HDAC inhibitor as the model thiol.

  2025cites this paper
• Kinetic and mechanistic investigation toward the characterization of tucatinib inhibition of CYP3A4.

  2025cites this paper
• CYP1A inhibitors: Recent progress, current challenges, and future perspectives

  2023cites this paper
• Non-innocuous Consequences of Metabolic Oxidation of Alkyls on Arenes.

  2022cites this paper
• Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes

  2022cites this paper
• Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach

  2022cites this paper
• Roles of human cytochrome P450 1A2 in coumarin 3,4-epoxidation mediated by untreated hepatocytes and by those metabolically inactivated with furafylline in previously transplanted chimeric mice.

  2021cites this paper
• Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions part 3: Difference in substrate specificity of human and rodent CYP1A2 and the refinement of predicting system.

  2019cites this paper
• Evaluation of Strategies for the Assessment of Drug–Drug Interactions Involving Cytochrome P450 Enzymes

  2018cites this paper
• Effets du diabète de type 2 sur l’expression et l’activité des cytochromes P450 hépatiques et extra-hépatiques chez la souris C57BL/6 sous une diète riche en gras

  2017cites this paper
• Metabolic Activation and Toxicities of Furanoterpenoids

  2016cites this paper
• Evaluation of tizanidine as a marker of canine CYP1A2 activity.

  2016cites this paper
• A Highly Selective Ratiometric Two-Photon Fluorescent Probe for Human Cytochrome P450 1A.

  2015cites this paper
• Inhibition of Cytochrome P450 Enzymes

  2015cites this paper
• Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation

  2015cites this paper
• Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4

  2014influential citation
• Microsoft Word-92403395-file00.docx

  2014influential citation
• Selective and sensitive platform for function-based screening of potentially harmful furans.

  2014cites this paper
• Bioactivation I: Bioactivation by Cytochrome P450s

  2012cites this paper
• Bioactivation and Inactivation of Cytochrome P450 and Other Drug‐Metabolizing Enzymes

  2012cites this paper
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011cites this paper
• Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.

  2011cites this paper
• Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms.

  2010cites this paper
• Characterization of Cytochrome P450 Mechanism-Based Inhibition

  2010cites this paper
• Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2

  2010cites this paper
• Inactivation of Human Cytochrome P450 Enzymes and Drug–Drug Interactions

  2010cites this paper
• Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.

  2009cites this paper
• In vitro micronucleus test in HepG2 transformants expressing a series of human cytochrome P450 isoforms with chemicals requiring metabolic activation.

  2009cites this paper
• Chapter 26 Mechanism-Based Inhibition of CYP3A4 and Other Cytochromes P450

  2009cites this paper
• Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry

  2009cites this paper
• Mechanism-Based Inactivation of Lung-Selective Cytochrome P450 CYP2F Enzymes

  2008cites this paper
• Inhibition of CYP1A2-mediated drug metabolism in vitro and in humans : With special emphasis on rofecoxib and other NSAIDs

  2008cites this paper
• Single mutations change CYP2F3 from a dehydrogenase of 3-methylindole to an oxygenase.

  2008cites this paper
• Cytochrome P450 Inactivation by Pharmaceuticals and Phytochemicals: Therapeutic Relevance

  2008cites this paper
• In Vitro Prediction and in Vivo Verification of Enantioselective Human Tofisopam Metabolite Profiles

  2007cites this paper
• Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions

  2007influential citation
• Identification of the protein targets of the reactive metabolite of teucrin A in vivo in the rat.

  2007cites this paper
• Mechanism-Based Inactivation of Lung-Selective Cytochrome P 450 CYP 2 F Enzymes

  2007cites this paper
• Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs

  2007cites this paper
• Mechanism of formation of the ester linkage between heme and Glu310 of CYP4B1: 18O protein labeling studies.

  2007cites this paper
• In vitro approaches to investigate mechanism-based inactivation of CYP enzymes

  2007cites this paper
• Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.

  2007cites this paper
• INVESTIGATION OF THE BIOTRANSFORMATION OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE BY PROSTAGLANDIN H SYNTHASE AND CYTOCHROME P450 2F

  2007cites this paper
• Characterization of the amino acid adducts of the enedial derivative of teucrin A.

  2006cites this paper
• A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.

  2006cites this paper
• Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions

  2006cites this paper
• An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

  2006cites this paper
• Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

  2005cites this paper
• High throughput P450 inhibition screens in early drug discovery.

  2005cites this paper
• Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme.

  2005cites this paper
• Enzyme kinetics for clinically relevant CYP inhibition.

  2005cites this paper
• Zafirlukast Metabolism by Cytochrome P450 3A4 Produces an Electrophilic α,β-Unsaturated Iminium Species That Results in the Selective Mechanism-Based Inactivation of the Enzyme

  2005cites this paper
• Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species

  2004cites this paper
• Mechanism-Based Inactivation of Human Cytochrome P4502C8 by Drugs in Vitro

  2004cites this paper
• Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.

  2004cites this paper
• Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.

  2004cites this paper
• Inhibition of human hepatic CYP isoforms by mGluR5 antagonists.

  2004cites this paper
• In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan.

  2003cites this paper
• The Journal of Toxicological Sciences

  2003cites this paper
• The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes.

  2002cites this paper
• Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses

  2002cites this paper
• Cytochrome P450 isoform-specific in vitro methods to predict drug metabolism and interactions

  2001influential citation
• Fluvoxamine‐theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2

  2001cites this paper
• Bioactivation of toxicants by cytochrome p450-mediated dehydrogenation mechanisms.

  2001cites this paper
• Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes.

  2000cites this paper
• A Fluorescent Cell-Based Assay for Cytochrome P-450 Isozyme 1A2 Induction and Inhibition

  2000cites this paper
• Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.

  1999cites this paper